Physician profile
Stephanie D Wright
NPI 1205078169
$1,982.39
in general payments reported to CMS, 2019-2025
21 companies · $778 in 2025
The $778 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.00 · 2022: $101 · 2023: $316 · 2024: $761 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,854.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $707.83 | 2022-2025 | Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $205.70 | 2023-2025 | Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $194.38 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $161.96 | 2023-2025 | Auvelity |
| Edwards Lifesciences Corporation | $100.00 | 2025 | Sapien 3 Ultra Resilia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $99.66 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $93.00 | 2024-2025 | Fanapt, Hetlioz |
| Pfizer INC. | $65.42 | 2024-2025 | |
| Ironshore Pharmaceuticals INC. | $48.74 | 2023-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $40.29 | 2025 | Qelbree |
| Merck Sharp & Dohme LLC | $39.00 | 2024-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $36.97 | 2023-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.00 | 2019 | |
| Lilly USA, LLC | $23.26 | 2022 | |
| Collegium Pharmaceutical, INC. | $21.98 | 2025 | Jornay Pm |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $21.76 | 2024 | Azstarys |
| Xeris Pharmaceuticals, INC. | $21.75 | 2024 | Gvoke Hypopen |
| Amgen INC. | $21.57 | 2025 | Krystexxa |
| Sage Therapeutics, LLC | $21.22 | 2024 | |
| Exact Sciences Corporation | $18.76 | 2025 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $13.14 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.